Biovica International
UPPSALA, SE / ACCESSWIRE / September 14, 2021 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)
Biovica, active in cancer diagnostics, today announces that DiviTumTKa results from the large BioItaLEE study will be presented as a poster during the European Society for Medical Oncology (ESMO) meeting 16 to 21 September 2021. The results strengthen the potential of DiviTum ® TKa as a treatment monitoring devise for CDK4/6 inhibitor treatments.
The results from a large independent study with a CDK4/6 inhibitor therapy and DiviTum ® TKa as a treatment monitoring assay in 287 patients with metastatic breast cancer is presented at the ESMO congress.
"I'm happy to see that the presented results on this CDK4/6 inhibitor ribociclib are consistent with earlier CDK4/6-results for example for palbociclib. The study results are highly encouraging as a reference for using DiviTum®TKa for the monitoring of CDK4/6 inhibitor treatments in HR positive metastatic breast cancer," said Anders Rylander, CEO of Biovica.
The study concludes that TKa appears to be a new promising prognostic, predictive and monitoring biomarker in patients with HR positive/HER2 negative metastatic breast cancer treated with ribociclib plus letrozole as first-line therapy. Baseline and dynamic TKa changes provided independent valuable information. Lack of TKa suppression at day 15 indicates enrichment for primary resistance and poor prognosis. TKa rebound at treatment cycle 2, day 1 may indicate early adaptation to ribociclib plus letrozole, while persistent suppression seems to identify patients with sustained inhibition and excellent prognosis.
Link to poster: https://cslide.ctimeetingtech.com/esmo2021/attendee/confcal_4/presentation/list?q=292P+-+
Contact
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum ® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se , +46 8 528 00 399. For more information please visit: www.biovica.com .
Attachments
Promising DiviTumTKa results from BioItaLEE study presented at ESMO
SOURCE: Biovica International
View source version on accesswire.com:
https://www.accesswire.com/663954/Promising-DiviTumTKa-Results-from-BioItaLEE-Study-Presented-at-ESMO
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Expands IBM Collaboration to Deploy Enterprise-Grade AI at the Edge with Available Infrastructure's SanQtum AI Platform8.1.2026 13:00:00 CET | Press release
Datavault AI will activate a secured multi-city edge AI network for real-time data tokenization, security, and monetization across New York and Philadelphia NEW YORK, NY / ACCESS Newswire / January 8, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in instant data monetization & enterprise digital twins, announced it will deliver enterprise-grade AI performance at the edge in New York and Philadelphia through an expanded collaboration with IBM using the SanQtum AI platform. Operated by Available Infrastructure, SanQtum AI is a fleet of synchronized micro edge data centers running IBM's watsonx portfolio of AI products on a zero-trust network. The combined deployment is designed to enable cybersecure data storage and compute, real-time data scoring, tokenization, and ultra-low-latency, across two of the most data-dense metro regions in the United States. By running Datavault AI's Information Data Exchange and DataScore agents - built with watsonx - within SanQtum AI's zero-trust edge e
Ascend Advanced Therapies - ABL Inc. Further Strengthens Executive Team as It Drives Forward an Ambitious Growth Strategy8.1.2026 13:00:00 CET | Press release
Seiga Ohmine to join as Chief Commercial Officer, Sharad Dubey as Chief Financial Officer and Patrick Lansky as Senior Vice President of Global Business Development Appointments underscore Ascend-ABL's commitment to scientific rigor, operational excellence, and strategic growth ROCKVILLE, MARYLAND / ACCESS Newswire / January 8, 2026 / Ascend Advanced Therapies - ABL Inc. today announced significant appointments to its leadership team. Seiga Ohmine Ph.D. joins as Chief Commercial Officer (CCO) Sharad Dubey CA, CPA joins as Chief Financial Officer (CFO) Patrick Lansky joins as Senior Vice President of Global Business Development These appointments reflect Ascend-ABL's focus on strengthening scientific leadership, operational discipline, and customer-centric execution as the company sharpens its positioning as a trusted CDMO partner for advanced viral modalities. Commenting on the appointments, Alessandra Rispoli, Chief Executive Officer of Ascend-ABL said, "We are making strong progress
Market Logic Announces Technology Partnership with Zappi to Accelerate Innovation with AI8.1.2026 08:00:00 CET | Press release
BERLIN, DE / ACCESS Newswire / January 8, 2026 / Market Logic Software is excited to announce a technology partnership with Zappi designed to help leading brands develop, refine, and test new product concepts faster than ever before. United by a joint agentic AI framework, this collaboration brings together advanced AI capabilities from both companies, marking a pivotal shift in how organizations execute insights-driven innovation. Through AI-to-AI integrations, linking two powerful AI platforms, enterprises can now enrich their product innovation process with a comprehensive data ecosystem. Specially trained DeepSights AI agents within Market Logic's Innovation Studio continuously monitor, analyse, and synthesize market research, news, and operational data-allowing for accelerated concept generation and more informed decision-making. With just a couple of clicks, customers can seamlessly progress to testing their concepts with real people, thanks to Zappi's real-world respondent solut
RE Royalties Announces up to a USD $9.0 Million Portfolio-Level Royalty Investment with Solaris Energy Inc.7.1.2026 22:20:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / January 7, 2026 / RE Royalties Ltd. (TSXV:RE)(OTCQX:RROYF) ("RE Royalties" or the "Company") is pleased to announce that it has entered into a definitive agreement with Solaris Energy Inc. ("Solaris") to invest up to USD $9.0 million to acquire a royalty interest (the "Royalty Purchase") in two portfolios of distributed generation ("DG") solar projects located throughout the United States. The first portfolio consists of 15 projects including 9 under construction with several nearing operation, and 6 in development, located across California, Maine, Delaware, New Hampshire and Colorado ("Portfolio 1"). The second portfolio comprises 9 more projects, the final composition of which may evolve as the projects advance ("Portfolio 2"). The transaction represents the acquisition of a portfolio level royalty on a diversified portfolio of DG solar assets and marks the exciting beginning of a new partnership between the two parties. The Royalty Purchase for Por
RAK ICC Provides Strategic Solutions for Holding Companies and Regional Expansion7.1.2026 13:35:00 CET | Press release
Focused on Stability, Regulatory Alignment, and Long-Term Business Growth RAS AL KHAIMAH, UAE / ACCESS Newswire / January 7, 2026 / As businesses face increasing regulatory complexity across borders, RAK ICC offers flexible solutions to simplify expansion and protect assets. RAK ICC offers a straightforward and globally aligned registration of holding companies for high net worth individuals, families and their advisors looking to manage investments, shareholding structures, and regional expansion. With a focus on regulatory compliance and operational efficiency, RAK ICC provides businesses with the tools needed to scale within the UAE and across the region. In an ever-changing global business landscape, RAK ICC allows businesses to operate within the UAE's well-established economic and legal frameworks, ensuring they meet both local and international standards while managing operations effectively. Key Features of RAK ICC's Platform: Streamlined Business Management: RAK ICC makes it e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom